May 14, 2026

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

Randomized trial suggests sustained clearance across darker skin tones.

Conexiant

May 14, 2026

UCI Health raises colon cancer awareness on “Dress in Blue Day”

UCI Health joined the national “Dress in Blue Day” campaign on March 10 to raise awareness.

UCI Health

May 14, 2026

Low-Dose Oral Minoxidil Monitoring Questioned

A retrospective hair clinic study found stable blood pressure, heart rate, weight, and laboratory measures during follow-up of up to 30 months.

Conexiant

May 14, 2026

When to Choose MRN Over Ultrasound

Proximal location, multi-nerve involvement, and multi-region extent favor MRN; ultrasound retains value for dynamic assessment and metal artifact–limited cases.

Conexiant

May 14, 2026

Physicians Exit Practice Earlier

Researchers identified burnout-associated workplace pressures and caregiving responsibilities as major contributors to physician attrition.

Conexiant

May 14, 2026

Sex Differences Seen in Immune Cells

Single-cell analysis identified sex-biased immune-cell composition, gene expression, and genetic regulation in unstimulated blood immune cells

Conexiant

May 14, 2026

Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?

A systematic review and meta-analysis found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers, with the association appearing to be ...

The ASCO Post

May 14, 2026

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonge...

The ASCO Post

May 14, 2026

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was associated with higher rates of excellent 90-day outcomes after inadequate tenecteplase response in selected stroke patients, though adjusted analyses were not significant.

Conexiant

May 14, 2026

Tenecteplase Prior to EVT Did Not Improve Stroke Outcomes

Phase 3 trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

Conexiant